Analysts Set Rallybio Co. (NASDAQ:RLYB) PT at $9.75

Rallybio Co. (NASDAQ:RLYB) has been given a consensus recommendation of “Hold” by the five analysts that are covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $9.33.

Several equities research analysts have recently commented on RLYB shares. Citizens Jmp lowered Rallybio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, April 8th. HC Wainwright restated a “neutral” rating on shares of Rallybio in a research report on Wednesday, April 9th.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. FMR LLC increased its position in shares of Rallybio by 1.1% during the 3rd quarter. FMR LLC now owns 2,315,480 shares of the company’s stock valued at $2,709,000 after purchasing an additional 25,422 shares during the last quarter. Almitas Capital LLC raised its position in Rallybio by 48.3% during the 4th quarter. Almitas Capital LLC now owns 1,298,119 shares of the company’s stock valued at $1,246,000 after purchasing an additional 422,685 shares in the last quarter. Allostery Investments LP purchased a new stake in shares of Rallybio in the 4th quarter worth approximately $771,000. Renaissance Technologies LLC lifted its stake in shares of Rallybio by 9.3% during the 4th quarter. Renaissance Technologies LLC now owns 441,318 shares of the company’s stock worth $424,000 after purchasing an additional 37,618 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Rallybio by 11.4% in the third quarter. Geode Capital Management LLC now owns 244,986 shares of the company’s stock valued at $287,000 after acquiring an additional 24,980 shares in the last quarter. Institutional investors own 90.34% of the company’s stock.

Rallybio Stock Up 8.0 %

Shares of NASDAQ:RLYB opened at $0.27 on Thursday. Rallybio has a 52 week low of $0.22 and a 52 week high of $2.01. The company’s fifty day moving average is $0.63 and its 200 day moving average is $0.88. The stock has a market cap of $11.24 million, a PE ratio of -0.17 and a beta of -1.35.

Rallybio (NASDAQ:RLYB) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.02. The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.15 million. Sell-side analysts anticipate that Rallybio will post -1.34 EPS for the current year.

About Rallybio

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.